PubMed:32178765 / 1267-1526 JSONTXT

{"target":"https://pubannotation.org/docs/sourcedb/PubMed/sourceid/32178765","sourcedb":"PubMed","sourceid":"32178765","source_url":"https://www.ncbi.nlm.nih.gov/pubmed/32178765","text":"Patients were randomly assigned (1:1:1, computer-generated permuted blocks; stratified by baseline DMARD and previous TNF inhibitor use) to subcutaneous guselkumab 100 mg every 4 weeks; guselkumab 100 mg at weeks 0, 4, then every 8 weeks; or matching placebo.","tracks":[{"project":"Inflammaging","denotations":[{"id":"T9","span":{"begin":0,"end":259},"obj":"Sentence"},{"id":"T9","span":{"begin":0,"end":259},"obj":"Sentence"}],"attributes":[{"subj":"T9","pred":"source","obj":"Inflammaging"},{"subj":"T9","pred":"source","obj":"Inflammaging"}]},{"project":"yaoziqian_800_3","denotations":[{"id":"T10","span":{"begin":251,"end":258},"obj":"CI"},{"id":"T8","span":{"begin":153,"end":163},"obj":"CI"},{"id":"T9","span":{"begin":186,"end":196},"obj":"CI"}],"attributes":[{"subj":"T10","pred":"source","obj":"yaoziqian_800_3"},{"subj":"T8","pred":"source","obj":"yaoziqian_800_3"},{"subj":"T9","pred":"source","obj":"yaoziqian_800_3"}]},{"project":"Zierdiyeerkenaili_800_3","denotations":[{"id":"T10","span":{"begin":153,"end":163},"obj":"CI"},{"id":"T11","span":{"begin":186,"end":196},"obj":"CI"},{"id":"T18","span":{"begin":251,"end":258},"obj":"CI"}],"attributes":[{"subj":"T10","pred":"source","obj":"Zierdiyeerkenaili_800_3"},{"subj":"T11","pred":"source","obj":"Zierdiyeerkenaili_800_3"},{"subj":"T18","pred":"source","obj":"Zierdiyeerkenaili_800_3"}]}],"config":{"attribute types":[{"pred":"source","value type":"selection","values":[{"id":"Inflammaging","color":"#93d5ec","default":true},{"id":"yaoziqian_800_3","color":"#ece993"},{"id":"Zierdiyeerkenaili_800_3","color":"#cf93ec"}]}]}}